NDTVCenter·
Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads
According to the Novo complaint, Lilly ads say people on Zepbound lost an average of 50 pounds, while Wegovy users lost an average of 33 pounds.
Read at NDTV →
Business · 1 sources covering this
Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads
According to the Novo complaint, Lilly ads say people on Zepbound lost an average of 50 pounds, while Wegovy users lost an average of 33 pounds.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/ab0af11920a7b0df67c67968691357393ad442be" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads"></iframe>
